Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
CONCLUSIONS: Sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer.PMID:33820779 | DOI:10.1158/1078-0432.CCR-20-4131
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Bora Lim David A Potter Mohamad A Salkeni Paula Silverman Tufia C Haddad Frederic Forget Ahmad Awada Jean-Luc Canon Michael Danso Alain Lortholary Hugues Bourgeois Elizabeth Tan-Chiu Sylvie Vincent Brittany Bahamon Kevin J Galinsky Chirag Patel Rachel Neu Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Hormones | Study | Women